title: Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
abstract: OBJECTIVE
  HIV/hepatitis C virus (HCV) coinfected patients are usually considered a difficult-to-treat population. The aim of this study was to assess the effectiveness of telaprevir-based and boceprevir-based treatments with respect to the HIV status.
  
  
  METHODS
  A prospective multicentre study was conducted among 22 Infectious Disease centres in Italy. Demographic, HIV and HCV related variables were collected, as well as data on HCV viral decay, sustained virologic response (SVR12) and grade 3-4 adverse events.
  
  
  RESULTS
  Overall, 162 patients (24.7% HIV/HCV coinfected) received HCV treatment. Out of 145 evaluable patients, 57.2% achieved SVR12 (49.5% monoinfected, 78.9% coinfected). HIV coinfection was associated with a slight increase in the probability of SVR12 (adjusted odds ratio 1.66, 95% confidence interval 0.59-4.64, P=0.33). Premature discontinuation rates and adverse events were similar irrespective of HIV status, with the exception of skin reactions, which were more frequently in the HIV group.
  
  
  CONCLUSIONS
  In a real-life setting, with a high proportion of cirrhotic and treatment-experienced patients, the overall SVR12 rate was 57.2%. HIV coinfection was not associated with impaired outcome.
authors.affiliation: aDepartment of Social Health (DISSAL), Division of Infectious Disease, University of Genoa-IRCCS San Martino-IST, Genoa bUnit of Infectious Diseases, Busto Arsizio Hospital, Busto Arsizio cEpi2004, Luigi Sacco Hospital dDepartment of Infectious Diseases, Luigi Sacco Hospital, Milan eInfectious Diseases Unit, AOU Careggi, Florence fInstitute of Infectious Disease, University of Bari, Bari gDepartment of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania hDivision of Infectious Diseases, 'Santo Spirito' Hospital, Pescara iDepartment of Clinical and Experimental Medicine, University of Sassari, Sassari jInfectious Diseases Unit, A. Manzoni Hospital, Lecco kInfectious Diseases Clinic, Università 'G. D'Annunzio', Chieti lUnit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze mDepartment of Infectious Diseases, Santa Maria Hospital, Perugia, Italy.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Nicolini
authors.forename: Barbara
authors.initials: B
authors.lastname: Menzaghi
authors.forename: Elena
authors.initials: E
authors.lastname: Ricci
authors.forename: Canio
authors.initials: C
authors.lastname: Martinelli
authors.forename: Carlo
authors.initials: C
authors.lastname: Magni
authors.forename: Paolo
authors.initials: P
authors.lastname: Maggi
authors.forename: Benedetto M
authors.initials: BM
authors.lastname: Celesia
authors.forename: Giustino
authors.initials: G
authors.lastname: Parruti
authors.forename: Sergio
authors.initials: S
authors.lastname: Babudieri
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonfanti
authors.forename: Katia
authors.initials: K
authors.lastname: Falasca
authors.forename: Francesca
authors.initials: F
authors.lastname: Vichi
authors.forename: Giuseppe V
authors.initials: GV
authors.lastname: De Socio
authors.forename: Elena
authors.initials: E
authors.lastname: Salomoni
authors.forename: Antonio
authors.initials: A
authors.lastname: Di Biagio
authors.forename: Tiziana
authors.initials: T
authors.lastname: Quirino
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; D012367:RNA, Viral; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D007372:Interferons; D011392:Proline